1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Thesis
3. Valuation & Price Target
4. Business & Product Moat
5. People & Governance
6. Market & Macro
7. Financial Quality
8. Risk Register
9. Prediction Market
10. 𝕏 Posts
Discussion
1. Investment Snapshot
2. Metrics vs Peers
3. Valuation
Discussion
Research report, target price, DCF and forensic scores are for subscribers. View plans
Symbol
RZRA
Sector
Health Care
Subsector
Pharmaceuticals
Offer Range
—
Shares Offered
—
—
Implied Upside vs Midpoint
Description
We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3, or NLRP3. NLRP3 is the upstream driver of sterile inflammation – inflammation that is caused by damage signals, such as cholesterol crystals or misfolded proteins, rather than by infection. NLRP3 activation triggers formation of the NLRP3 inflammasome, an intracellular protein complex involved in the body’s inflammatory response. NLRP3 activation directly stimulates the production of interleukin-1 beta, or IL-1β, and interleukin-18, or IL-18, which are potent pro-inflammatory cytokines. In turn, IL-1β stimulates production of another inflammatory molecule, interleukin-6, or IL-6. For this reason, this inflammatory cascade is referred to as the NLRP3/ IL-1β/IL-6/IL-18 pathway. When NLRP3 becomes chronically activated, it stimulates this cascade of inflammatory mediators that drive the development and progression of cardiovascular and neuroinflammatory disease. This phenomenon of chronically elevated inflammation that persists and contributes to disease progression even when other known risk factors are well controlled, is known as RIR. The presence of RIR can be assessed using a widely available biomarker called high-sensitivity C-Reactive Protein, or hsCRP, which is a well-validated independent risk factor for future cardiovascular events, and hsCRP can also be used to evaluate whether inflammatory activity of the NLRP3/ IL-1β/IL-6/IL-18 pathway has been reduced by a therapeutic intervention. By directly inhibiting NLRP3 upstream, we aim to broadly reduce the activity of the entire sterile inflammation pathway, thereby reducing RIR and modifying the course of cardiovascular and neurologic diseases. --- We have been a leader in the research, discovery and development of NLRP3 inhibitors for over a decade, and we have designed our portfolio to address historical challenges faced by other NLRP3 inhibitors: potency, therapeutic index and tissue penetration. Our lead product candidate, ruvonoflast, is highly potent, has been observed to be well tolerated in five completed human clinical trials and in an extensive nonclinical toxicology program, and is designed to achieve broad tissue distribution, including penetration into the central nervous system, or CNS. We plan to develop ruvonoflast in peripheral artery disease, or PAD, as our lead indication. PAD is a form of atherosclerotic cardiovascular disease, or ASCVD, in which narrowed or blocked small arteries reduce blood flow to the limbs, most commonly the legs. We subsequently plan to expand development to establish ruvonoflast in ASCVD more broadly. In PAD, our goal is to demonstrate that ruvonoflast is a disease-modifying anti-inflammatory therapy for patients with PAD. We selected PAD because it represents a significant unmet medical need in a large patient population and is associated with a high inflammatory burden and substantial disease morbidity despite broad use of lipid-lowering, antihypertensive and diabetes therapies. PAD affects approximately 20 million adults in the United States, driving $21 billion in annual direct health care costs. We believe ruvonoflast may address a market opportunity of approximately $5 billion, based on reasonable assumptions for penetration rate, price, reimbursement and competition. In addition, PAD offers a focused commercial opportunity through a concentrated network of treatment centers. We believe PAD is an attractive initial indication because RIR is an important driver of disease progression. More than half of the approximately 20 million adults with diagnosed ASCVD have RIR. We believe PAD provides an opportunity to evaluate the impact of ruvonoflast in a patient population with significant unmet need, and to establish a foundation for the future development of ruvonoflast in broader ASCVD populations. PAD impairs circulation to the legs and significantly reduces quality of life, walking performance and functional status as the disease progresses. Intermittent claudication (pain on walking), which is the hallmark symptom of symptomatic PAD, can limit daily activities and mobility, reduce exercise capacity and cause progressive functional decline. In early stages of PAD, patients have a two-fold increased risk of cardiovascular death, which rises to approximately four times the risk in later stages. Late-stage disease progression is also characterized by leg ulcerations, ischemia and ultimately amputation, and may result in chronic limb-threatening ischemia, or CLTI. CLTI is the most advanced stage of PAD and affects more than two million patients in the United States and is associated with a high risk of limb loss. PAD is also a leading cause of non-traumatic lower-extremity amputation in the United States, with approximately 150,000 non-traumatic lower-extremity amputations occurring annually. NLRP3-driven inflammation plays a prominent role in the origin and progression of PAD. NLRP3 expression is elevated in the lower extremity arteries of people with PAD. People with genetically lower IL-6 and IL-18 levels have been observed to have lower rates of PAD, and people with genetically higher rates of NLRP3 activation have been observed to have early onset of PAD in adolescence. Eighty percent of patients with PAD have elevated high-sensitivity C-reactive protein, or hsCRP, a blood-based biomarker of inflammation that is an independent risk factor for cardiovascular risk. Higher hsCRP and IL-6 levels in patients with PAD have been linked to faster loss of walking ability and higher rates of serious limb and cardiovascular events. However, the current standard of care in PAD focuses on improving blood flow, reducing clotting and treating traditional risk factors such as lipids and blood pressure. There are no approved therapies that directly target the underlying inflammatory pathways in PAD. Ruvonoflast is designed to target inflammatory mechanisms that contribute to PAD progression but are not addressed by current standard-of-care therapies. To date, we have not conducted clinical trials of ruvonoflast in patients with PAD. Our clinical data for ruvonoflast comes from trials conducted in other indications, including cardiometabolic and neuroinflammatory disease populations, where we have observed reductions in hsCRP, IL-18, IL-6 and fibrinogen (an independent risk factor for thrombosis). Taken together, these biomarker changes indicate deep and broad inhibition of the NLRP3 inflammation pathway. In a clinical trial of calorie-restricted patients with high cardiovascular risk, ruvonoflast reduced hsCRP by 82% (versus 37% with placebo), and significantly reduced these additional pro-inflammatory molecules associated with atherogenesis and thrombosis. We believe these results are relevant to PAD because hsCRP, IL-6 and fibrinogen are also elevated in patients with PAD and have been linked to faster loss of walking ability and higher rates of limb and cardiovascular events. Based on the observed biomarker reductions in our non-PAD clinical trials, together with the established role of NLRP3-mediated inflammation in PAD progression, we believe ruvonoflast has the potential to improve walking distance and quality of life and may ultimately be able to prevent or delay disease progression and reduce adverse limb and cardiovascular outcomes in patients with PAD. We have evaluated ruvonoflast in cardiometabolic disease in our RESOLVE-1 Phase 2 clinical trial. This clinical trial demonstrated geometric LSmean hsCRP reduction of 56.4% at 150 mg QD and 62.6% at 150 mg BID at week 4. Furthermore, hsCRP was reduced below 2 mg/L in 33% and 40% of patients at 150 mg QD and at 150 mg BID doses of ruvonoflast, respectively, and there were reductions in additional biomarkers: median IL-6 by 38.2% and 62.3% and median fibrinogen by 19.0% and 17.8%, at 150 mg QD and at 150 mg BID, respectively. Additionally, we have discussed our plan to conduct a single well-controlled Phase 3 trial with the U.S. Food and Drug Administration, or the FDA, the European Medicines Agency, or the EMA, and the Medicines and Healthcare products Regulatory Agency, or MHRA, and we plan to initiate our Phase 3 PAD trial in the first half of 2027. Approximately 20 million adults in the United States have diagnosed ASCVD, and the disease drives significant annual costs in the United States. Despite advances in the treatment of ASCVD to address the role of lipids, hypertension, thrombosis and diabetes in the origin and progression of the disease, 30% of people with ASCVD have RIR as measured by elevated hsCRP. Similar to PAD, there is no approved therapy that directly targets the inflammatory pathways that contribute to disease progression in this broad population. The rationale for targeting inflammation in ASCVD is supported by data from multiple third-party clinical trials, including: . The Canakinumab Anti-inflammatory Thrombosis Outcome Study, or CANTOS, initiated in 2011 with primary completion in 2017, evaluated more than 10,000 patients and demonstrated a reduction in major adverse cardiovascular events, or MACE, among patients who achieved lower levels of inflammation. In CANTOS, quarterly canakinumab in post-myocardial infarction patients with elevated hsCRP reduced major adverse cardiovascular events by 25% in patients who achieved hsCRP reduction below 2 mg/L. This was achieved without altering lipids, providing strong clinical evidence that lowering IL-1β–mediated inflammation (independent of cholesterol) reduces cardiovascular risk. . The Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin, or the JUPITER trial, demonstrated that in healthy men and women with low-density lipoprotein, or LDL, cholesterol <130 mg/dL but elevated hsCRP≥2 mg/L, rosuvastatin 20 mg daily produced large reductions in LDL and hsCRP and significantly lowered the incidence of first major cardiovascular events compared with placebo (Hazard Ratio ~0.56). The JUPITER trial was stopped early at a median of 1.9 years because of clear benefit, including a reduction in all-cause mortality. This trial provides evidence that the modest anti-inflammatory effects of rosuvastatin could impact outcomes in patients without elevated lipids. . In patients with established ASCVD, multiple trials (notably LoDoCo2 and COLCOT) show that adding low-dose colchicine 0.5 mg daily to guideline-directed therapy reduces MACE by roughly 25–30%, supporting inflammation-targeted therapy as an effective strategy to lower residual ASCVD risk. We believe ruvonoflast has the potential to meet the significant unmet need in the ASCVD treatment landscape and may offer several advantages over the monoclonal antibodies that have been investigated in the field. Namely, ruvonoflast has an oral route of administration, the potential for combination products, and a low observed and theoretical risk of immune suppression. In addition, ruvonoflast has been designed to achieve high levels of tissue penetration, which may allow it to have increased activity at sites of inflammation such as the vascular wall and other extravascular tissues, as well as for high levels of brain penetration which may allow it to offer therapeutic and/or preventive effects in the brain in patients with cardiovascular disease. We also plan to develop ruvonoflast in indications beyond PAD and ASCVD. We believe that ruvonoflast’s high observed tissue and brain penetration in humans could support development in a range of cognitive and neurological diseases that have an association or overlap with ASCVD. We plan to develop and disclose our expanded development strategy for ruvonoflast in the future. In addition to ruvonoflast, we are developing trabzanoflast (formerly known as NT-0150), which is an NLRP3 inhibitor designed to be brain-penetrant and achieve CNS exposure and selective upstream inhibition of NLRP3-driven neuroinflammation. We believe that trabzanoflast is differentiated from ruvonoflast by its chemical structure and its optimization specifically for CNS penetration. This design supports NLRP3 inhibition as a potential therapeutic approach in neuroinflammatory diseases. We anticipate that trabzanoflast may benefit from the growing body of clinical and translational evidence generated across our NLRP3 inhibitor portfolio. Trabzanoflast has completed its Phase 1 clinical trial and has demonstrated activity in NLRP3 in vitro models and reduced neuroinflammation in CNS nonclinical models. Emerging evidence implicates activation of NLRP3 as a contributor to neuroinflammation and neurodegeneration across multiple disorders, including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis and other CNS disorders. Our development plan for trabzanoflast will focus on neuroinflammatory indications. --- NodThera Limited was originally formed and registered in Scotland in July 2016 and was the ultimate parent company of a former subsidiary known as NodThera Inc., or OldCo, until NodThera US, Inc., or NewCo, was incorporated in the State of Delaware in December 2021. In January 2022, NodThera Limited sold all of its capital stock in OldCo to NewCo and became a subsidiary of NewCo. Following this transaction, OldCo merged with and into NewCo, with NewCo as the surviving corporation. Upon finalization of the merger, NewCo was renamed NodThera Inc. In September 2026, we changed the name of our company from NodThera Inc. to Rezera Inc. We have two subsidiaries, Rezera Securities Corporation, formed under the laws of the Commonwealth of Massachusetts, and NodThera Limited, formed under the laws of the United Kingdom. We maintain an office at 265 Franklin Street, Suite 1702, Boston, Massachusetts, which serves as our principal executive office. We also maintain additional office space at our location in the United Kingdom at Suite 8, The Mansion, Chesterford Research Park, Little Chesterford, CB10 1XL, Cambridge, United Kingdom. Our telephone number: (617) 694-2481. Our website address is www.rezera.com.
| Metric | Value | Peer median | Among peers | |
|---|---|---|---|---|
9 premium metrics: DCF value / price, Growth the price needs: how common, Last 12 months vs full year and 6 more Unlock | ||||